Cardiology, Klinikum Lichtenfels, Lichtenfels, Germany.
Cardiology, Klinikum Hochrhein, Waldshut-Tiengen, Germany.
Catheter Cardiovasc Interv. 2021 Jun 1;97(7):E973-E981. doi: 10.1002/ccd.29271. Epub 2020 Sep 15.
This study compares procedural and late clinical outcomes of left atrial appendage closure (LAAC) with Amplatzer devices as a single versus a combined procedure with other structural or coronary interventions.
Multiple cardiac conditions are frequent among elderly patients and invite simultaneous treatment to ensure a favorable patient outcomes.
559 consecutive patients (73.3 ± 11.1 years) underwent LAAC with Amplatzer devices at two centres (Bern and Zurich university hospitals, Switzerland) either as a single procedure or combined with other interventions. The primary safety endpoint was a composite of major peri-procedural complications and major bleeding at follow-up, the primary efficacy endpoint included stroke, systemic embolism, and cardiovascular/unexplained death. All event rates are reported per 100 patient-years.
In 263 single and 296 combined procedures with percutaneous coronary interventions (47.6%), closure of an atrial septal defect (8.4%) or a patent foramen ovale (36.5%), transcatheter aortic valve implantation (10.1%), mitral clipping (4.1%), atrial fibrillation ablation (8.8%), or another procedure (3.0%) were analyzed. Device success (96.6% [single] vs. 99.0% [combined], p = .08) did not differ between the groups. After a mean follow-up of 2.6 ± 1.5 vs. 2.5 ± 1.5 years and a total of 1,422 patient-years, the primary efficacy (40/677, 5.9% [single] vs. 37/745, 5.0% [combined]; HR, 1.2, 95% CI, 0.8-1.9, p = .44), as well as the primary safety endpoint (25/677, 3.7% vs 28/745, 3.8%; HR, 1.0, 95% CI, 0.6-1.8, p = .89) were comparable.
LAAC with Amplatzer devices combined with structural, coronary, and electrophysiological procedures offers procedural feasibility and safety, as well as long-term efficacy.
本研究比较了左心耳封堵(LAAC)与 Amplatzer 装置作为单一手术与联合其他结构性或冠状动脉介入治疗的手术过程和晚期临床结果。
老年患者常同时患有多种心脏疾病,需要同时进行治疗以确保患者获得良好的预后。
在瑞士伯尔尼和苏黎世大学医院的两个中心,559 例连续患者(73.3±11.1 岁)接受了 Amplatzer 装置的 LAAC,要么作为单一手术,要么与其他介入治疗联合进行。主要安全性终点是围手术期主要并发症和随访时主要出血的复合终点,主要疗效终点包括卒中和全身性栓塞以及心血管/不明原因死亡。所有事件发生率均按每 100 患者年报告。
在 263 例单一手术和 296 例联合经皮冠状动脉介入治疗(47.6%)、房间隔缺损(8.4%)或卵圆孔未闭(PFO)关闭(36.5%)、经导管主动脉瓣植入术(10.1%)、二尖瓣夹闭(4.1%)、心房颤动消融术(8.8%)或其他手术(3.0%)中进行了分析。两组之间的器械成功率(96.6%[单一]与 99.0%[联合],p=0.08)没有差异。在平均 2.6±1.5 年和总计 1422 患者年的随访后,主要疗效(40/677,5.9%[单一]与 37/745,5.0%[联合];HR,1.2,95%CI,0.8-1.9,p=0.44)和主要安全性终点(25/677,3.7%与 28/745,3.8%;HR,1.0,95%CI,0.6-1.8,p=0.89)相当。
Amplatzer 装置联合结构性、冠状动脉和电生理程序的 LAAC 提供了手术可行性和安全性以及长期疗效。